• BioMarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 64 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 18 cents. The mean expectation of twenty eight analysts for the quarter was for earnings of 53 cents per share. Wall Street expected results to range from 43 cents to 74 cents per share.

• Revenue rose 15.6% to $747.31 million from a year ago; analysts expected $713.44 million.

• BioMarin Pharmaceutical Inc's reported EPS for the quarter was 64 cents​.

• The company reported quarterly net income of $124.94 million.

• BioMarin Pharmaceutical Inc shares had fallen by 1.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $94.50

This summary was machine generated from LSEG data February 19 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)